VRBCF · Virbac SA
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since Mar 23, 2026; less than a full year is stored.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VRBCF
this stock
Virbac SA
|
$3.21B | — | — | — | 0.0% |
|
LLY
ELI LILLY & Co
|
$1.34T | +32.8% | +44.7% | 46.3 | 0.8% |
|
JNJ
Johnson & Johnson
|
$682.52B | +37.0% | +6.0% | 43.1 | 0.7% |
|
ABBV
AbbVie Inc.
|
$520.47B | +28.9% | +8.6% | 50.7 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$362.27B | +39.6% | +1.3% | 151.5 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VRBCF | +18.1% | +18.3% | — | -6.1% | +10.8% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | +19.1% | +16.4% | — | -6.2% | +1.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.